MEHMET OKCU to Biomarkers, Tumor
This is a "connection" page, showing publications MEHMET OKCU has written about Biomarkers, Tumor.
Connection Strength
0.458
-
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers. JCO Precis Oncol. 2025 Feb; 9:e2400556.
Score: 0.122
-
A novel case of malignant ossifying fibromyxoid tumor with a BCOR internal tandem duplication in a child. Pediatr Blood Cancer. 2023 03; 70(3):e29972.
Score: 0.103
-
Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. Cancer Epidemiol. 2016 10; 44:161-166.
Score: 0.068
-
Long-term outcome of centrally located low-grade glioma in children. Cancer. 2013 Jul 15; 119(14):2630-8.
Score: 0.054
-
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol. 2009 Dec; 11(6):825-32.
Score: 0.043
-
CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg. 2004 Oct; 39(10):1506-11.
Score: 0.030
-
Neuroendocrine Tumor of the Appendix in Children. J Pediatr Hematol Oncol. 2017 03; 39(2):97-102.
Score: 0.018
-
Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer. 2011 Jan 01; 117(1):207-17.
Score: 0.011
-
Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neuroblastoma. J Pediatr Surg. 2007 Jan; 42(1):148-52.
Score: 0.009